checkAd

     463  0 Kommentare MorphoSys Announces Clinical Milestone in Blood Disorders Program - Seite 2

     

    HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

    Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

     

     

    This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

     

     


     

    For more information, please contact:

    MorphoSys AG

    Dr. Claudia Gutjahr-Löser

    Head of Corporate Communications & IR

     

    Mario Brkulj

    Associate Director Corporate Communications & IR

     

    Alexandra Goller

    Manager Corporate Communications & IR

     

    Jessica Rush

    Manager Corporate Communications & IR

     

    Tel: +49 (0) 89 / 899 27-404

    investors@morphosys.com






    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: MorphoSys AG via Globenewswire

    HUG#1940533

    --- End of Message ---

    MorphoSys AG
    Lena-Christ-Str. 48 Martinsried / Munich Germany

    WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
    Listed: Freiverkehr in Börse Stuttgart,
    Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
    Freiverkehr in Börse Berlin,
    Freiverkehr in Börse Düsseldorf,
    Freiverkehr in Bayerische Börse München,
    Freiverkehr in Niedersächsische Börse zu Hannover,
    Prime Standard in Frankfurter Wertpapierbörse,
    Regulierter Markt in Frankfurter Wertpapierbörse;


    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    MorphoSys Announces Clinical Milestone in Blood Disorders Program - Seite 2 MorphoSys AG / MorphoSys Announces Clinical Milestone in Blood Disorders Program . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. MorphoSys AG (FSE: MOR; Prime …

    Schreibe Deinen Kommentar

    Disclaimer